|
|
|
|
|
|
|
|
|
| |
|
| |
| |  Dr. Shattock and collaborators in the U.K. and South Africa will attempt to develop an HIV vaccine that stimulates immunity to the virus in the lining of the vagina. The investigators hypothesize that an HIV vaccine will be most effective at the site where the virus enters the body. Innovative combinations of vaccine antigen formulas and delivery technologies will be used to develop a potentially potent and effective vaccine. The vaccine will be designed to be delivered via low-cost vaginal gels or via silicone rings that fit inside the vagina and can be self-administered. The gel and ring will be formulated with a mechanism to release the vaccine in small amounts over time. |
| | |
| | | Develop an HIV vaccine that stimulates immunity to the virus | | |
| |
| | BACK TO THE TOP |
| | | | | |
| | | University of York, York, United Kingdom - GB | | | | | Imperial College, London, London, United Kingdom - GB | | | | | University of Oxford, Oxford, United Kingdom - GB | | | | | Queen’s University, Belfast, Belfast, United Kingdom - GB | | | | | National Institute for Biological Standards and Control, Potters Bar, United Kingdom - GB | | | | | Particle Sciences, Inc., Pennsylvania, United States - US | | | | | University of Lleida, Lleida, Spain - ES | | | | | Polymun Scientific, Vienna, Austria - AT | | | | | Constella Group, Ltd., Abingdon, United Kingdom - GB | | | | | Dr. Michael Seaman, Beth Israel Deaconess Medical Center, Massachusetts, United States - US | | |
| |
| | BACK TO THE TOP |
|
|
|
|
|
|
|
|
|
|
|